Prescription drug · NDA
Rasonque (daraxonrasib) NDC 85219-104
Daraxonrasib 150 mg/1 · Tablet, Film coated · Oral · Revolution Medicines, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 85219-104-01 | 85219010401 | 1 BOTTLE in 1 CARTON (85219-104-01) / 30 TABLET, FILM COATED in 1 BOTTLEMarketed from Aug 26, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Rasonque
- Generic name (nonproprietary)
- daraxonrasib
- Active ingredients
- Daraxonrasib — 150 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Revolution Medicines, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220910
- Marketing start
- Listing expires
- Identifiers
- Product ID 85219-104_107d4cd9-2e5e-419d-9449-7ef84f5fbcc9SPL ID 107d4cd9-2e5e-419d-9449-7ef84f5fbcc9SPL set ID 13a65923-d072-4dac-8620-8eabbf8c3641RxCUI 2750160, 2750166, 2750168, 2750170UNII B6T47Y2UAPUPC 0385219101015
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N485219010401followed by a unit qualifier and the quantityPackage 85219-0104-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 220910
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Rasonquedaraxonrasib | Daraxonrasib 100 mg/1 | Tablet, Film coatedOral | Revolution Medicines, Inc. | 85219-101 |
| Rasonquedaraxonrasib | Daraxonrasib 100 mg/100mg | Tablet, Film coatedOral | Shanghai SynTheAll Pharmaceutical Co., Ltd. | 24538-430 |
| Rasonquedaraxonrasib | Daraxonrasib 150 mg/150mg | Tablet, Film coatedOral | Shanghai SynTheAll Pharmaceutical Co., Ltd. | 24538-435 |